Enlicitide
Enlicitide decanoate (oral macrocyclic peptide PCSK9 inhibitor)
Written by Aaron CuhaReviewed Sep 2026
Also known as: Enlicitide decanoate, MK-0616, Lipfendra
The first PCSK9 inhibitor you can swallow. A macrocyclic peptide that cut LDL cholesterol by 57 percent in 2,909 people, in a class that until now required injection.
Overview
PCSK9 inhibitors lower LDL cholesterol dramatically and, until 2026, all of them were injections. Enlicitide is a macrocyclic peptide engineered to survive the gut and be absorbed as a once-daily tablet, which is a genuinely hard problem: peptides are normally destroyed by digestion, and its oral bioavailability is around one percent even with an absorption enhancer. That one percent is enough. In the CORALreef Lipids trial, 2,909 adults with established cardiovascular disease or at risk of a first event were randomised to enlicitide or placebo. LDL cholesterol fell 57.1 percent against a 3.0 percent rise on placebo. It is worth knowing about even if you never take it, because it is proof that an oral peptide can hit a target that previously required a needle.
Mechanism of action
Binds PCSK9 and blocks it from binding the LDL receptor. PCSK9 normally marks LDL receptors for destruction, so inhibiting it leaves more receptors on the liver surface to clear LDL from the blood. The oral delivery relies on a macrocyclic structure resistant to gut proteases, combined with an absorption enhancer.
Human evidence
Substantial and recent. This is one of the better-evidenced compounds in this catalogue, with a large randomised placebo-controlled phase 3 published in a top journal and a regulatory approval behind it.
- CORALreef Lipids: 2,909 participants, randomised, double-blind, placebo-controlled, 52 weeks. Primary endpoint met with a 55.8 percentage point between-group difference in LDL cholesterol.
- Secondary endpoints for non-HDL cholesterol, apolipoprotein B and lipoprotein(a) all favoured enlicitide.
- A separate phase 3 compared it against existing oral nonstatin therapies rather than against placebo.
What this does not tell you: Every trial so far measures cholesterol, not events. Lowering LDL is strongly linked to fewer heart attacks across the wider drug literature, but a cardiovascular outcome trial for this specific drug has not reported. The trials are manufacturer funded, which is normal for a drug programme and worth stating.
Reading the research record
Enlicitide matters to this site for a reason beyond cholesterol. The standing assumption about peptides is that they cannot be taken orally, because digestion destroys them, which is why almost every peptide in this catalogue is an injection. Enlicitide is a working counterexample at scale: a 1,722 dalton macrocycle that survives the gut well enough, at roughly one percent bioavailability, to produce a 57 percent LDL reduction in nearly three thousand people.
That has implications for the whole category. If macrocyclisation plus an absorption enhancer can deliver a peptide this size orally, the list of targets that require a needle gets shorter. Watch this space rather than this molecule.
The evidence, charted
Fig. 1 · evidence composition
3of 3 citations (100%) are in people
Every citation cited here is Human work; no other study type is cited on this page. This count is of our own citation list and understates any literature larger than the sources we cite.
Fig. 2 · evidence over time
Every citation here was published in 2026.
Too few distinct publication years on this page to plot as a timeline.
Fig. 3 · legal status at a glance
US
Approved
UK
Prescription
AU
Prescription
CA
Prescription
Approved in 1 of 4, prescription route in 3, not approved in 0. A jurisdiction's classification is a regulatory fact, not a verdict on the science; see Legal status below for the full text and any notes.
Key studies & citations
- Human2026
A placebo-controlled trial of the oral PCSK9 inhibitor enlicitide
2,909 participants randomised 2:1 to enlicitide 20 mg or placebo for 52 weeks. LDL cholesterol fell 57.1 percent at week 24 against a 3.0 percent rise on placebo, an adjusted between-group difference of 55.8 percentage points (p < 0.001). Non-HDL cholesterol, apolipoprotein B and lipoprotein(a) also improved. Funded by the manufacturer.
New England Journal of Medicine - Human2026
Oral PCSK9 inhibitor enlicitide versus oral nonstatin therapies: a phase 3 randomized clinical trial
Randomised comparison of enlicitide against the existing oral nonstatin options rather than against placebo alone.
Journal of the American College of Cardiology - Human2026
CORALreef Lipids trial record
The registered protocol for the pivotal placebo-controlled trial.
ClinicalTrials.gov
Frequently asked questions
Is this the first oral PCSK9 inhibitor?
Yes. Every previously approved PCSK9 inhibitor is an injection. Enlicitide is a macrocyclic peptide engineered to survive digestion and be taken as a daily tablet.
How much does it lower LDL?
57.1 percent at 24 weeks in the pivotal trial, against a 3.0 percent rise on placebo, in 2,909 people. That is comparable to the injectable drugs in the same class.
Does it prevent heart attacks?
That has not been shown for this drug yet. The trials measured cholesterol. Lowering LDL is strongly associated with fewer cardiovascular events across the broader literature, but the outcome trial for enlicitide specifically has not reported.
Why does one percent bioavailability still work?
Because the target is in the liver, which is the first organ the drug reaches after absorption, and because the dose is set to deliver enough despite the loss. It is an engineering solution rather than a biological one.